Inlyta 7 mg (Axitinib Tablet) 7mg

Inlyta 7 mg (Axitinib) is an oral tablet used for advanced kidney cancer treatment. This targeted therapy helps slow disease progression by blocking specific cancer cell signals. Suitable for adults, it provides a convenient at-home option for cancer care.

Strength

7mg

Pack Size

28s

Storage

Ambient

Manufacturer / TM Owner

Pfizer Switzerland

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Inlyta 7 mg (Axitinib) is prescribed to treat advanced renal cell carcinoma, a type of kidney cancer. It works by targeting and blocking signals that help cancer cells grow and spread. This medication is typically used when other treatments have not been effective. Patients may take it as part of a broader cancer management plan.

Side Effects

Inlyta 7 mg (Axitinib) may help reduce tumor growth and manage symptoms associated with advanced kidney cancer. Common effects include fatigue, nausea, or digestive changes. Some patients report improved energy levels or appetite over time. Individual responses vary based on treatment duration and health status.

Precautions & Warnings

Store Inlyta 7 mg (Axitinib) at room temperature away from moisture and heat. Keep the medication in its original packaging until ready to use. Avoid crushing or splitting tablets unless advised by a healthcare provider. Handle with care to prevent accidental exposure or contamination.

Avoid Interactions

Inlyta 7 mg (Axitinib) may interact with certain medications, including strong CYP3A4 inhibitors or inducers. Grapefruit products can affect how the drug is processed in the body. Always inform your doctor about all prescription, over-the-counter, and herbal products you are taking. Alcohol use should be discussed with a healthcare professional.

Frequently Asked Questions

Inlyta 7 mg (Axitinib) is used to treat advanced kidney cancer in adults when other treatments are not effective.

Store Inlyta 7 mg at room temperature, away from moisture and heat, in its original packaging.

Do not crush or split Inlyta 7 mg tablets unless instructed by a healthcare provider.

Yes, grapefruit products may interact with Inlyta 7 mg and affect how the medication works.

Inlyta 7 mg is a targeted therapy, not a traditional chemotherapy medication.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.